Form 4: Evolent Health CEO Seth Blackley Receives Significant RSU Grant

Evolent Health, Inc. CEO Seth Blackley was granted 67,150 restricted stock units on July 1, 2025, as part of the company's annual incentive compensation plan, following shareholder approval.

Summary

• Seth Blackley, the Chief Executive Officer and a Director of Evolent Health, Inc. (EVH), was granted 67,150 Class A Common Stock restricted stock units (RSUs).
• The transaction date for this RSU grant is July 1, 2025.
• These RSUs were granted at a price of $0, which is typical for equity incentive awards.
• The granted RSUs will vest over three years: 34% on July 1, 2026, 33% on July 1, 2027, and the remaining 33% on July 1, 2028.
• This specific portion of the award was approved by the Compensation Committee as part of the annual award cycle and was contingent upon shareholder approval of the issuance of additional shares under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• Shareholders approved the issuance of additional shares under the plan on June 5, 2025, at the Company's Annual Meeting.
• Following this transaction, Mr. Blackley's direct beneficial ownership of Class A Common Stock, including previously reported RSU awards, totals 829,367 shares.

Sentiment

Score: 7

Explanation: The document reports a standard executive compensation event (RSU grant) which aligns management incentives with shareholder interests. Shareholder approval of the underlying plan is a positive governance sign. There are no overtly negative financial implications beyond standard dilution from equity compensation.

Positives

• The RSU grant aligns the interests of the CEO, Seth Blackley, directly with those of shareholders, as the value of the award is tied to the company's stock performance.
• The multi-year vesting schedule (through July 2028) encourages long-term retention and sustained performance from the CEO.
• Shareholder approval of additional shares for the 2015 Omnibus Incentive Compensation Plan on June 5, 2025, demonstrates investor support for the company's long-term equity incentive strategy.

Negatives

• The issuance of new shares for RSU grants can lead to dilution for existing shareholders, although the specific impact depends on the total number of shares outstanding and the relative size of the grant.

Risks

• Potential future dilution of existing shareholders as the restricted stock units vest and convert into common stock.

Future Outlook

The RSU grant and its vesting schedule indicate a long-term incentive structure for the CEO, aligning future compensation with the company's performance through July 2028.

Industry Context

Executive compensation, particularly through equity grants like RSUs, is a standard practice across industries, including healthcare technology, to incentivize leadership and align their interests with long-term shareholder value. The approval of incentive plans by shareholders is a common corporate governance practice.

Comparison to Industry Standards

• The granting of restricted stock units to a CEO as part of an annual incentive cycle is a common practice in publicly traded companies, particularly in the healthcare technology sector.
• The multi-year vesting schedule (3 years) is also standard, designed to promote long-term retention and performance.
• While the specific number of units (67,150) and the total beneficial ownership (829,367 shares) would need to be compared against the company's market capitalization and peer group compensation data (e.g., CEOs of companies like Teladoc Health, Amwell, or Veeva Systems) for a detailed assessment, the mechanism itself aligns with typical industry benchmarks for executive equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon RSU vesting, but also benefit from increased alignment of CEO incentives with long-term stock performance.
• Employees: The grant is part of an 'annual award cycle' under an 'Omnibus Incentive Compensation Plan,' suggesting a broader framework for employee incentives, which could positively impact morale and retention.

Next Steps

• Vesting of 34% of RSUs on July 1, 2026.
• Vesting of 33% of RSUs on July 1, 2027.
• Vesting of 33% of RSUs on July 1, 2028.

Key Dates

Recommendation

Keywords

Evolent Health, EVH, Seth Blackley, Restricted Stock Units, RSU, Executive Compensation, Incentive Plan, Form 4, SEC Filing, Corporate Governance, Shareholder Approval, Stock Grant